Last edition
News about "Meiji Seika Pharma "
Meiji Seika Pharma Invests in Centivax for Universal Vaccine Platform
Meiji Seika Pharma invests in Centivax to advance a next-generation universal vaccine platform, with lead candidate Centi-Flu 01 currently in a Phase 1 influenza study.
Meiji Seika Pharma | 31/03/2026 | By News Bureau
Meiji Seika Pharma Initiates Phase I Trial of ME3241 PD-1 Agonist Antibody for Autoimmune Diseases
Meiji Seika Pharma Co., Ltd. has launched a Phase I clinical trial of ME3241, a novel anti-PD-1 agonist antibody developed with Foundation for Biomedical Research and Innovation at Kobe for autoimmune disease treatment.
Meiji Seika Pharma | 16/03/2026 | By News Bureau | 120
Meiji Seika Pharma Establishes Local Subsidiary Taiwan Meiji Pharma
Meiji Seika Pharma aims to become ‘a company in Asia in the field of infectious diseases’ as part of the ‘Meiji Group 2026 Vision’ targeting the year 2026.
Meiji Seika Pharma | 26/12/2024 | By Aishwarya | 562
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy